12,372 trials
Depressive Disorder, Major
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Study — -4.9; -4.8; -5.4 Score on a Scale — p=0.8862
Diabetes Mellitus, Non-Insulin-Dependent · High Risk for Cardiovascular Event
Primary: Subjects Included in the Composite Endpoint of CV Death, MI or Ischemic Stroke — 756; 803 Participants — p=0.172
Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Primary: Time to Adjudication Committee (AC)-Determined Neuromyelitis Optica Spectrum Disorder (NMOSD) Attack During RCP — NA; NA Days — p=<0.0001
BACTERIAL VAGINOSIS · Signs and Symptoms to be Evaluated and Recorded Include · Vaginal Discharge Color, Odor, and Consistency
Primary: Number of Participants With Both a Clinical and a Bacteriological Cure (Nugent Score <4), Evaluated at Visit 2 Test-of-cure (Study Day 22-30). — 36; 34; 9 Participants
Atrophic Vaginitis
Primary: Number of Participants Identified as a Responder After Completing Study Treatment in the Generic Estradiol Vaginal Cream and Estrace Vaginal Cream Groups — 49; 44…
Caries, Dental · Cariostatic Agents
Primary: Microbial Levels — 11; 7; 15; 15 Participants — p=0.35
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -1.3; -0.9; -1.5; -0.9 Percentage-point of HbA1c — p=< 0.0001
Opioid-induced Bowel Dysfunction
Primary: Number of Participants Classified as Treatment Responders Within 12 Weeks — 59; 41 Participants
Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children
Primary: Mean Change From Baseline to TC 1, Week 6 in MAS Score in the TC 1 PTMG — -1.5; -1.9; -2.2 score on a scale — p=0.0118
Cerebral Vein Thrombosis · Deep Vein Thrombosis · Gonadal Thrombosis
Primary: 6 Month Bleeding Rate — 0; 2.1 percentage of patients
Major Depressive Disorder
Primary: Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score — -22.48; -22.94; -24.22 units on a scale
Severe Hemophilia A
Primary: Pharmacokinetic (PK) Assessment (Area Under the Curve (AUC)) of FVIII:C — 768.8; 671.9; 720.3 h*IU/dL
Pediatric Hypertension
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 19; 5 Participants
Hepatitis C Virus (HCV)
Primary: Percentage of HCV GT1 - GT6-Infected Participants in Arm A Who Achieved Sustained Virologic Response 12 Weeks Post Treatment (SVR12) — 97.2 percentage of participants
Colitis, Ulcerative · Inflammatory Bowel Diseases
Primary: Induction Study - Number of Participants With Clinical Remission at Week 8 (As Per Global Definition) — 17; 50; 50 Participants — p=< 0.001